104 results about "Immunologic Stimulation" patented technology

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The present invention relates to a composition for enhancing immunity, containing, as an active ingredient, a polysaccharide enzyme-treated product derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified polysaccharide fraction thereof. The composition for enhancing immunity according to the present invention, comprising the polysaccharide enzyme-treated product of the mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora or the novel purified polysaccharide fraction thereof, is composed of specific types and contents of sugars and significantly increases the activity of macrophages, splenocytes, and NK cells upon application thereto, thereby being applicable as an immunopotentiator or a composition for enhancing immunity.

The present invention relates to the technical field of biomedicine, and in particular to an adjuvant composition, a respiratory syncytial virus (RSV) vaccine composition, and a use thereof. An aluminum adjuvant and a CpG ODN adjuvant are combined in proportion to form an adjuvant composition. An RSV vaccine composition comprising the adjuvant composition has better immunostimulatory activity, can enable early induction of a high humoral immune response, can maintain a strong cellular immune response for a long time, can produce an immune response comparable to that of a licensed vaccine Arexvy, and is a safe, effective and promising human RSV candidate vaccine.

The present invention relates to the field of vaccines, and in particular to a novel adjuvant polypeptide sequence and a use thereof. The adjuvant polypeptide sequence provided by the present invention comprises amino acid sequences of tetanus toxoid epitopes P2 and P16 and further comprises amino acid sequences of P30 and / or PX. The adjuvant polypeptide sequence aims to expand the coverage population of immune responses by increasing epitope diversity. In addition, the present invention uses an LNP (lipid nanoparticle) delivery system to introduce an mRNA encoding an adjuvant polypeptide and an initial antigen protein into a human body, thereby improving the immunostimulatory ability of the initial antigen. The adjuvant polypeptide sequence provided by the present invention and the initial antigen sequence are preferably fused, thereby simplifying the composition of mRNA in a nucleic acid vaccine and reducing the complexity of vaccine preparation.

The invention provides a preparation method and application of a nitrogen-containing heterocyclic micromolecule modified polyethyleneimine polymer derivative. Compared with a polyethyleneimine polymer, the nitrogen heterocyclic ring micromolecule modified polyethyleneimine polymer derivative provided by the invention has immunostimulatory activity. Besides, the polymer derivative material provided by the invention can be simply mixed with a protein antigen to form nanoparticles, so that efficient loading of the protein antigen is realized, the delivery efficiency of the protein antigen to lymph nodes is improved, and the polymer derivative material can be used for preparing a novel nano vaccine preparation.

The present invention provides an siRNA that inhibits angiopoietin-like 4 (ANGPTL4) gene expression, wherein the siRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises at least 17 continuous nucleotides that differ by no more than 4 nucleotides from the nucleotide sequences as shown in SEQ ID NO: 143, and the antisense strand is 17 to 30 nucleotides in length; the sense strand is 17 to 30 nucleotides in length and is at least partially complementary to the antisense strand. The siRNA, siRNA conjugate, and pharmaceutical composition provided in the present invention exhibit good stability, ANGPLT4 gene inhibitory activity, and immunostimulation, and can significantly reduce ANGPTL4 protein concentrations at the animal level.

Devices and methods for obtaining immunostimulatory antigen presenting cells. The present invention relates to methods for producing immunostimulatory antigen presenting cells. The invention also relates to the use of such cells for treating a patient suffering from a hyperproliferative disease, such as cancer.

The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.

This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.

The present disclosure provides engineered mesenchymal stem cells (MSCs), a pharmaceutical composition containing the same, and use thereof in the manufacture of a medicament for treating cancer. The mesenchymal stem cells (MSCs) comprise an introduced NQO1 protein-coding sequence and / or an introduced hypoxia response element (HRE), and a nucleic acid encoding one or more immunostimulatory cytokines.

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and / or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

An immunotherapeutic mRNA vaccine comprises a first translation unit comprising a secretable first fusion protein comprising a co-stimulatory molecule fused to a first TAA, adapted to generate a first TAA specific adaptive immune response by way of a first immunostimulatory pathway. The immunotherapeutic mRNA vaccine also comprises a second translation unit comprising a non-secretable second fusion protein comprising an identical co-stimulatory molecule fused to a second TAA identical to the first TAA, adapted to generate a second TAA specific adaptive immune response by way of a second immunostimulatory pathway, whereby the at least two immune response interact at one or more locations downstream to amplify the first TAA specific adaptive immune response.

Methods and compositions for the treatment of viral infections, such as HIV infection, are disclosed herein. In certain embodiments, a molecular conjugate comprising a viral capture domain and an immunostimulant molecule is provided.

To provide an immunostimulatory bacterial delivery platform and its use for delivery of therapeutic products.SOLUTION: Provided are immunostimulatory bacteria containing genomic modifications and plasmids encoding one or more therapeutic products, e.g., an anti-cancer therapeutic agent or a related treatment. The genome modification results in the immunostimulatory bacteria accumulating in tumor resident immune cells within the tumor microenvironment, where the encoded therapeutic product is expressed. The immunostimulatory bacteria provided herein encode one or more of the complementation products that stimulate, induce or result in a robust anti-cancer response in a subject.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

The present application provides vaccines comprising an inactivated influenza virus and an adjuvant comprising a triterpenoid saponin, a sterol, and an immunostimulatory oligonucleotide comprising CpG. Also provided are methods of using such vaccines.

The invention provides a Babylonia areolata larva disease-resistant cultivation method based on immunostimulation, and aims to solve the problems of frequent larva diseases and low survival rate in intensive cultivation. The method comprises the following steps: selecting Babylonia areolata of Thailand and Hainan populations for reciprocal cross to obtain hybrid filial generations; in the larva stage, a compound immunologic stimulant compounded by astragalus polysaccharide, peptidoglycan and beta-glucan is adopted, the concentration is accurately regulated and controlled according to the early, middle and late stages of the daughter larvae and the creeping stage, and alternate induction is conducted through water splashing and bait mixing and feeding; when the larva shell length is 30-50mm, vibrio harveyi sublethal infection is used for enhancing immune memory, and environmental parameters such as water temperature and salinity are synchronously regulated and controlled. Tests show that the method can significantly improve the growth performance, immune enzyme activity and disease resistance of larvae, the survival rate of cultivation reaches 95% or above, the natural morbidity is lower than 6%, and technical support is provided for large-scale healthy cultivation of Babylonia areolata.

The present invention provides an adjuvant composition comprising QS21, 3D-MPL and an immunostimulatory oligonucleotide which comprises a purine, purine, C, G, pyrimidine, pyrimidine sequence.

The present disclosure relates in part to methods of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a retinaldehyde dehydrogenase 1 (RALDH1) inhibitor and an immunostimulator. The present disclosure further relates to pharmaceutical compositions comprising an RALDH1 inhibitor and an immunostimulator.

The invention discloses a composite milk adjuvant, a preparation method and application of the composite milk adjuvant in vaccines, and belongs to the technical field of medicines. The technical problems to be solved are relatively weak cell immunocompetence, relatively poor immunogenicity and relatively weak immunoregulation capability. According to the technical scheme, squalene, polyoxyethylated castor oil 35 and poloxamer 407 are used as raw materials to prepare a basic formula of the milk adjuvant, an immunologic stimulant is added on the basis to prepare the composite milk adjuvant, and the physicochemical properties and safety of the composite milk adjuvant are represented. The synergistic effect of the milk adjuvant on humoral immunity and cellular immunity is further evaluated by being matched with a recombinant tuberculosis antigen Ag85B to immunize mice, and data support is provided for application of the milk adjuvant in development of novel vaccines such as tuberculosis vaccines and the like. The composite milk adjuvant prepared by the invention not only keeps good humoral immunity and induces generation of high-level IgG1 and IgG2a, but also remarkably improves the response level of cellular immunity.

Provided are an immunomodulatory CpG ODN chemically modified by means of a structure as shown by general formula I and the use thereof. The CpG ODN has an immunostimulatory activity, can stimulate the proliferation of B cells, and produce specific cytokines. The above-mentioned CpG ODN can be used as a vaccine adjuvant alone or in combination with other adjuvants to exert a synergistic effect, and can also be used in the preparation of drugs for preventing or treating tumors, infections, and allergies.

The present invention relates to cancer immunotherapy. In particular, the present invention provides methods, compounds, compositions and kits for treating and / or preventing cancer. Specifically, provided are methods for the treatment of cancer comprising administering a TLR2 agonist, such as a conjugate of dipalmitoyl-S-glyceryl-cysteine (Pam2Cys) and polyethylene glycol (PEG), more specifically a Pam2Cys-Ser-PEG compound, and an immunostimulatory agent, such as an anti-PD-1, anti-PDL-1, anti-PL-1, or anti-CTLA-4 immunotherapeutic agent.

Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen-binding domain that specifically binds TGF-β, a peptide spacer, a transmembrane domain, and an endodomain. When expressed in a cell, the polypeptides are capable of not only neutralizing the TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.

This invention provides an siRNA that inhibits the expression of the MMP7 gene, comprising a sense strand and an antisense strand. The siRNA according to this invention has good stability, excellent MMP7 gene inhibitory activity, negligible cytotoxicity and immunostimulant activity, and can significantly reduce MMP7 protein levels at the animal level. It has significant clinical value in the treatment of diseases or conditions that benefit from the reduction of MMP7 levels or inhibition of its expression.

The present invention relates to a composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof. According to the present invention, the composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof, comprises specific types and contents of sugars. Thus, when macrophages, splenocytes, and NK cells are treated with the composition, the composition significantly increases the activities thereof, and therefore can be applied as an immunostimulant or a food composition for enhancing immunity.

The invention provides a method for quantitatively analyzing immune response strength promoted by an adjuvant and application of the method in adjuvant screening, and relates to the technical field of vaccine adjuvants. According to the method for quantitatively analyzing the immune response strength promoted by the adjuvant, the immune response level of the to-be-detected adjuvant can be predicted only by taking the control adjuvant as a reference substance and taking the number of KikGR red fluorescent cells 6-120 hours after immunostimulation of the combined antigen as an index. The method has the characteristics of noninvasive and continuous tracing, simplifies the flow and period of adjuvant effect evaluation, improves the screening efficiency, reduces the research and development period, and provides an effective technical means for rapid screening of adjuvants.

The present invention provides immunostimulatory nucleic acids that have an affinity to a specific target protein. The present invention also provides templates and methods for making and using the immunostimulatory nucleic acids. Further, methods for linking the immunostimulatory nucleic acids to antigens and using the resulting complexes to enhance an immune response are provided.

The present invention relates to a composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof. According to the present invention, the composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof, comprises specific types and contents of sugars. Thus, when macrophages, splenocytes, and NK cells are treated with the composition, the composition significantly increases the activities thereof, and therefore can be applied as an immunostimulant or a food composition for enhancing immunity.

The present disclosure provides for compounds including modified saponin compounds, pharmaceutical compositions including modified saponin compounds, methods of use of the modified saponin compounds and the pharmaceutical compositions, methods of making modified saponin compounds, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating viral infection and other diseases.